Fasting-Mimicking Diet Increases Anti-Tumor Immunity
Research suggests short bursts of intense calorie restriction could improve treatment response in patients with a range of cancers.
Progress Against Cancer
Research suggests short bursts of intense calorie restriction could improve treatment response in patients with a range of cancers.
Medical oncologist Lola Fashoyin-Aje describes the Food and Drug Administration’s efforts to make clinical trials more inclusive.
Success of immune checkpoint inhibitors in clinical trials does not always carry over to patients in the clinic.
Is it the beginning of the end or the end of the beginning?
Many cancer patients have problems with memory or thinking that can linger for years after treatment. The cause is a mystery, but new tactics are helping many people cope with its effects.
The FDA has approved a radioactive compound and companion diagnostic test for patients with advanced prostate cancer. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for adult...
The FDA approved pembrolizumab for certain patients with advanced endometrial cancer with DNA repair defects The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) for the treatment of adult patients with advanced...
Metastatic prostate cancer incidence rose after recommendation against routine screening, and FDA approves first PARP inhibitor for early-stage breast cancer for people with inherited BRCA mutations.
The FDA approved nivolumab and relatlimab-rmbw (Opdualag) for some patients with advanced melanoma The U.S. Food and Drug Administration (FDA) has approved a combination of the checkpoint inhibitors nivolumab and relatlimab-rmbw (Opdualag) for...
Pediatric patients whose cancer had relapsed were successfully matched to new gene-targeted therapies in large European trial, according to a study in the AACR journal Cancer Discovery.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More